NasdaqGS - Delayed Quote USD

Poseida Therapeutics, Inc. (PSTX)

Compare
2.4500 -0.0900 (-3.54%)
At close: October 18 at 4:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for PSTX

Recent News: PSTX

View More
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche
MaxCyte Appoints Cynthia Collins to its Board of Directors

MaxCyte Appoints Cynthia Collins to its Board of Directors
Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024

Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients

Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients
FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1

FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting

Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting
Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma

Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma
Poseida Therapeutics to Present at Upcoming Investor Conferences

Poseida Therapeutics to Present at Upcoming Investor Conferences
Poseida Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Poseida Therapeutics Second Quarter 2024 Earnings: Beats Expectations
Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates

Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates
View More

Related Tickers